×
About 6,785 results

ALLMedicine™ Hypercalcemia Center

Research & Reviews  1,781 results

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Jun 24th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Studies of Inherited Diseases of Metabolism
https://clinicaltrials.gov/ct2/show/NCT00001345

Jun 24th, 2022 - Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypopa...

A patient with hypercalcemia and hyperparathyroidism due to adenoma mimicking multiple ...
https://doi.org/10.1111/ijlh.13919
International Journal of Laboratory Hematology; Lin H, Wu M et. al.

Jun 24th, 2022 - A patient with hypercalcemia and hyperparathyroidism due to adenoma mimicking multiple myeloma.|2022|Lin H,Wu M,Wang Z,Liu J,|

Giant cystic parathyroid adenoma: two case reports and a literature review.
https://doi.org/10.1177/03000605221106419
The Journal of International Medical Research; Weng J, Zhou W et. al.

Jun 24th, 2022 - An uncommon cause of primary hyperparathyroidism is a cystic parathyroid adenoma. This paper describes two patients with hypercalcemia and right knee disease. Their serum calcium concentration was high, phosphorus concentration was low, and parath...

see more →

Guidelines  3 results

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494249
Journal of Clinical Oncology : Official Journal of the Am... Cook LB, Fuji S et. al.

Jan 19th, 2019 - Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diver...

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0023
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Feb 12th, 2017 - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-r...

SEOM guidelines on hydroelectrolytic disorders.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239780
Clinical & Translational Oncology : Official Publication ... De las Peñas R, Escobar Y et. al.

Oct 12th, 2014 - Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often metabolic alterations affecting various ions are part of the manifestations of the oncological disease, even in the form of paraneopl...

see more →

Drugs  524 results see all →

Clinicaltrials.gov  154 results

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Jun 24th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Studies of Inherited Diseases of Metabolism
https://clinicaltrials.gov/ct2/show/NCT00001345

Jun 24th, 2022 - Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypopa...

Effect of Mechanical Loading on vBMD and Geometry in Patients With Primary Hyperparathyroidism
https://clinicaltrials.gov/ct2/show/NCT05426512

Jun 22nd, 2022 - Postmenopausal women with primary hyperparathyroidism will be included in the study. The diagnosis of primary hyperparathyroidism is based on the high levels of parathyroid hormone and calcium. Postmenopausal women with kidney failure, liver failu...

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04634552

Jun 21st, 2022 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Talquetamab is a humanized immunoglobulin G4 proline, alanine, alanine (IgG4PAA) bi...

A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy
https://clinicaltrials.gov/ct2/show/NCT02595489

Jun 9th, 2022 - Prior research suggests that higher vitamin D levels in the blood are associated with reduced brain inflammation among individuals with multiple sclerosis, a disease that is similar to the cerebral demyelinating form of ALD. However, serious side ...

see more →

News  243 results

Nab-Paclitaxel Plus Pembrolizumab Produces Promising Responses in Advanced Urothelial Cancer
https://www.onclive.com/view/nab-paclitaxel-plus-pembrolizumab-produces-promising-responses-in-advanced-urothelial-cancer

May 2nd, 2022 - The combination of nab-paclitaxel (Abraxane) and pembrolizumab (Keytruda) produced an encouraging overall response rate (ORR) with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or ...

FDA Grants Orphan Drug Designation to Toripalimab for Small Cell Lung Cancer
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-toripalimab-for-small-cell-lung-cancer

Apr 21st, 2022 - The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer (SCLC), according to an announcement from Coherus BioSciences, Inc. and Shanghai Junshi Bio...

Surgery Shows No Survival, Morbidity Benefit for Mild Hyperparathyroidism
https://www.medscape.com/viewarticle/972299

Apr 18th, 2022 - Patients who receive parathyroidectomy for mild primary hyperparathyroidism show no benefits in survival or morbidity, including fractures, cancer, or cardiovascular outcomes over more than 10 years, when compared with those not receiving the surg...

Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survival
https://www.medpagetoday.com/hematologyoncology/myeloma/96496

Jan 4th, 2022 - Multiple myeloma at a younger age did not portend more aggressive disease or worse outcomes but significantly shortened lifespan as compared with the general population without myeloma, according to one of the largest studies of its kind. Over a 1...

Enobosarm Generates Overdue Excitement in AR+/ER+ Metastatic Breast Cancer
https://www.onclive.com/view/enobosarm-generates-overdue-excitement-in-ar-er-metastatic-breast-cancer

Dec 27th, 2021 - After decades of research, investigators are hopeful that the nonsteroidal selective androgen receptor (AR) agonist enobosarm could become an important treatment strategy following CDK4/6 inhibition in patients with AR-positive, estrogen receptor ...

see more →

Patient Education  9 results see all →